Bharat Biotech | COVAXIN
Centre ropes in more PSUs, pumps money to increase Bharat Biotech's Covaxin production to 10 crore per month by Sept
New Delhi/IBNS: Amid the steep rise in Covid-19 cases, the Centre on Friday said it is taking steps to increase and accelerate the production of indigenous vaccines under Atma Nirbhar Bharat 3.0 Mission COVID Suraksha.
Bharat Biotech's production capacity will be increased to 10 crore doses per month.
Under the effort, the Department of Biotechnology is providing financial support as a grant to the companies manufacturing the Covid-19 vaccine to boost their production.
"The current production capacity of indigenously developed Covaxin vaccine will be doubled by May-June 2021 and then increased nearly 6-7 fold by July-August 2021 i.e increasing the production from 1 crore vaccine doses in April 2021 to 6-7 crore vaccine dose/month in July- August. It is expected to reach nearly 10 crore doses per month by Sep 2021," according to a release issued by Union Ministry of Science & Technology.
As a part of this augmentation plan, capacities of Bharat Biotech Limited, Hyderabad as well as other public sector manufactures are being upgraded with required infrastructure and technology.
Financial support is being provided as grant by the Centre to the tune of nearly Rs 65 Cr to Bharat Biotech’s new Bangalore facility which is being repurposed to increase the capacity of vaccine production.
Three public sectors companies are also being supported to increase the capacity of vaccine production.
Haffkine Biopharmaceutical Corporation Ltd, Mumbai, a Mumbai-based public sector enterprise of the Maharashtra government has been already allowed to produce Covaxin.
"Financial support as grant from GoI to the tune of appx Rs 65 Cr will be provided for this facility to be made ready for manufacturing. The Haffkine Biopharmaceuticals Ltd had asked for around 12 months to complete this task. However, the Central government has asked them to expedite and complete the task urgently within 6 months. The facility will have a capacity of 20 million doses per month, once functional," said the release.
Indian Immunologicals Limited (IIL), Hyderabad –a facility under National Dairy Development Board and Bharat Immunologicals and Biologicals Limited (BIBCOL), Bulandshahr, a CPSE under Department of Biotechnology, will also be supported to prepare their facility to provide 10-15 million doses per month by August to September.
Support Our Journalism
We cannot do without you.. your contribution supports unbiased journalism
IBNS is not driven by any ism- not wokeism, not racism, not skewed secularism, not hyper right-wing or left liberal ideals, nor by any hardline religious beliefs or hyper nationalism. We want to serve you good old objective news, as they are. We do not judge or preach. We let people decide for themselves. We only try to present factual and well-sourced news.
Support objective journalism for a small contribution.
